Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marius M Hoeper

Showing results (221-230 of 311) with videos related to

Pageof 32
Sort By:
Frontiers in Psychiatry|June 17, 2021
Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial HypertensionKaren M Olsson, Tanja Meltendorf, Jan Fuge, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 9, 2024
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE studyRaymond L Benza, Gérald Simonneau, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|February 20, 2025
A Long-Term Follow-Up Study of Sotatercept for Treatment of Pulmonary Arterial Hypertension: Interim Results of SOTERIAIoana R Preston, David Badesch, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|September 11, 2017
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitorsMarius M Hoeper, Gérald Simonneau, Paul A Corris, et al.
Circulation|June 28, 2024
Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 StudyMarius M Hoeper, Britta Oerke, Max Wissmüller, et al.
Critical Care (London, England)|April 5, 2022
Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational studyNina Rittgerodt, Thorben Pape, Markus Busch, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 24, 2020
Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantationFabio Ius, Khalil Aburahma, Dietmar Boethig, et al.
Ebiomedicine|July 11, 2020
Reappearance of effector T cells is associated with recovery from COVID-19Ivan Odak, Joana Barros-Martins, Berislav Bošnjak, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 4, 2017
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI<sub>2</sub>) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) studyIoana R Preston, Richard N Channick, Kelly Chin, et al.
American Journal of Respiratory and Critical Care Medicine|January 31, 2002
Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertensionMarius M Hoeper, Nazzareno Galié, Srinivas Murali, et al.
Pageof 32

Showing results (221-230 of 311) with videos related to

Sort By:
Pageof 32
Frontiers in Psychiatry|June 17, 2021
Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial HypertensionKaren M Olsson, Tanja Meltendorf, Jan Fuge, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 9, 2024
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE studyRaymond L Benza, Gérald Simonneau, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|February 20, 2025
A Long-Term Follow-Up Study of Sotatercept for Treatment of Pulmonary Arterial Hypertension: Interim Results of SOTERIAIoana R Preston, David Badesch, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|September 11, 2017
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitorsMarius M Hoeper, Gérald Simonneau, Paul A Corris, et al.
Circulation|June 28, 2024
Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 StudyMarius M Hoeper, Britta Oerke, Max Wissmüller, et al.
Critical Care (London, England)|April 5, 2022
Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational studyNina Rittgerodt, Thorben Pape, Markus Busch, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 24, 2020
Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantationFabio Ius, Khalil Aburahma, Dietmar Boethig, et al.
Ebiomedicine|July 11, 2020
Reappearance of effector T cells is associated with recovery from COVID-19Ivan Odak, Joana Barros-Martins, Berislav Bošnjak, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 4, 2017
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI<sub>2</sub>) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) studyIoana R Preston, Richard N Channick, Kelly Chin, et al.
American Journal of Respiratory and Critical Care Medicine|January 31, 2002
Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertensionMarius M Hoeper, Nazzareno Galié, Srinivas Murali, et al.
Pageof 32